For research use only. Not for therapeutic Use.
Simotinib is a small-molecule tyrosine kinase inhibitor (TKI) that targets epidermal growth factor receptor (EGFR) mutations, commonly associated with non-small cell lung cancer (NSCLC). By inhibiting EGFR signaling, simotinib disrupts the pathways that drive cancer cell proliferation and survival. It has shown promise in preclinical studies for its ability to reduce tumor growth and enhance the effectiveness of other cancer therapies. Simotinib represents a potential targeted treatment option for patients with EGFR-mutant NSCLC, offering a more personalized approach to cancer therapy.
| Catalog Number | I009492 |
| CAS Number | 944258-89-3 |
| Synonyms | N-(3-chloro-4-fluorophenyl)-6-[2-(5,8-dioxa-10-azadispiro[2.0.44.33]undecan-10-yl)ethoxy]-7-methoxyquinazolin-4-amine |
| Molecular Formula | C25H26ClFN4O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H26ClFN4O4/c1-32-21-12-20-17(23(29-15-28-20)30-16-2-3-19(27)18(26)10-16)11-22(21)33-7-6-31-13-24(4-5-24)25(14-31)34-8-9-35-25/h2-3,10-12,15H,4-9,13-14H2,1H3,(H,28,29,30) |
| InChIKey | OXWUWXCJDBRCCG-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCN4CC5(CC5)C6(C4)OCCO6 |
